The ENZO 798 is a super power behind-the-ear hearing aid that is Made for iPhone. The Nucleus Bimodal Solution is the first and only bimodal solution Made for iPhone. A bimodal hearing solution, compared to two hearing aids, is proven to help people understand speech and improve clarity of words in various listening situations.1,2,3
Cochlear and ReSound – partners in the Smart Hearing Alliance – are excited to announce the launch of the ReSound ENZO 3D 798 hearing aid as part of the Nucleus Bimodal Solution. Cochlear’s SMARTBimodal Solutions are designed to work together helping your patients to connect to the people they love, stream phone calls, videos, music and entertainment directly to both ears. No extra devices are necessary. This allows recipients to hear their best in the most challenging of environments.
Recipients now have two options when choosing the Nucleus Bimodal Solution. The bimodal solution consists of the Cochlear™ Nucleus® 7 Sound Processor and either the ReSound LiNX 3D 762 or ENZO 3D 798 hearing aids.
If you would like to order the Nucleus Bimodal Solution, please use the Nucleus Implant and Initial Activation order form and the Nucleus Bimodal Solution order form. Our Smart Care phone number is available to you for any questions you may have in regards to ordering the Nucleus Bimodal Solution: 1-877-883-3101.
Visit our professional webpage on the Smart Bimodal Solution for more information.
Gottermeier L, De Filippo C, Clark C. Trials of a Contralateral Hearing Aid After Long-Term Unilateral Cochlear Implant Use in Early-Onset Deafness. American journal of audiology. 2016 Jun 1;25(2):85-99.
Dorman MF, Gifford RH, Spahr AJ, McKarns SA. The benefits of combining acoustic and electric stimulation for the recognition of speech, voice and melodies. Audiology and Neurotology. 2008;13(2):105-12.
Gifford RH, Dorman MF, McKarns SA, Spahr AJ. Combined electric and contralateral acoustic hearing: Word and sentence recognition with bimodal hearing. Journal of Speech, Language, and Hearing Research. 2007 Aug 1;50(4):835-43.